Core Viewpoint - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. expects a net profit of 42 million to 48.5 million yuan for the fiscal year 2025, representing a growth of 79.59% to 107.38% compared to the same period in 2024, driven by cost control and supply chain management [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 42 million to 48.5 million yuan for 2025, marking a significant increase from the previous year [1] - Non-recurring gains and losses are expected to impact net profit by approximately 4 million yuan [1] Product and Market Position - The core support for the company's performance comes from its unique products, Yuanhu Zhiting Droplets and Xuanfei Zhiso Mixture, which maintain strong market positions [2] - A new production line for Xuanfei Zhiso Mixture with an annual capacity of 50 million boxes has passed GMP compliance checks and commenced production in August 2025 [2] Research and Development - The company has upgraded its research facilities and established multiple R&D platforms, including a significant acquisition of 70% of Gansu Pharmaceutical Group Technology Innovation Research Institute [3] - The company is advancing its product development, including the registration application for a new drug, and has launched several health products to enhance its product portfolio [3] International and Diversification Efforts - The company achieved important milestones in internationalization, with its health product, Huangqi Danggui Capsules, receiving official certification in Macau, facilitating market expansion [4] - New medical products, including blood dialysis powder and concentrated solutions, have received regulatory approval, paving the way for future production and sales [4]